CTAS vs NVAX · P/E 51, rev $11.26B vs P/E 2.5, rev $196.2M
Cintas Corporation (CTAS) versus Novavax Inc (NVAX) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Novavax Inc (NVAX) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Not investment advice. Open the CTAS and NVAX stock pages for the full models.
Not investment advice.